Vivo Bio Tech Reports Q4FY26 Loss Amid Auditor Concerns

Vivo Bio Tech Ltd announced its audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026. The company reported a consolidated net loss of ₹5.16 crore for the quarter, a widening from the previous year's comparable period. For the full year ended March 31, 2026, the consolidated net loss stood at ₹1.71 crore.

Reader Takeaway: Net loss continues, with auditor flagging statutory dues as a key concern.

What just happened

The company reported a consolidated revenue from operations of ₹14.20 crore for the fourth quarter ended March 31, 2026. This compares to a net loss of ₹5.16 crore for the same period. The full-year consolidated revenue was ₹53.33 crore, with a net loss of ₹1.71 crore.

On a standalone basis, revenue for the quarter was ₹13.77 crore, and the net loss was ₹5.44 crore. The full-year standalone revenue was ₹52.57 crore, with a net loss of ₹1.94 crore.

Why this matters

Investors are closely watching the company's financial performance, which shows continued losses. More critically, the statutory auditors, P Murali & Co., issued an 'Emphasis of Matter' in their report. This highlights that Vivo Bio Tech has not been regular in depositing certain undisputed statutory dues, amounting to a total of ₹4.18 crore.

These dues include ₹1.90 crore in Income Tax (Self-Assessment), ₹1.51 crore in TDS, ₹0.61 crore in Provident Fund, ₹0.11 crore in Professional Tax, and ₹0.06 crore in ESI.

The backstory

Vivo Bio Tech operates in the biotechnology sector. While specific financial performance history requires deeper analysis, the current results indicate a challenging period. The auditor's emphasis on statutory dues points to potential cash flow or liquidity management issues that have persisted.

What changes now

The board has approved several strategic developments. A consultant has been appointed to advise on a proposed Scheme of Arrangement/Amalgamation, suggesting potential corporate restructuring. Additionally, material related party transactions were approved, which will be put to shareholders for approval via a postal ballot.

In leadership, Mr. Kalyan Ram Mangipudi has been re-appointed as Whole-time Director for a five-year term starting July 29, 2026.

Risks to watch

The primary risk for investors is the company's continued unprofitability and the significant outstanding statutory dues. Failure to resolve these dues could lead to penalties or operational disruptions. The proposed scheme of arrangement also introduces uncertainty regarding the future structure and value proposition of the company.

Context metrics

• Q4 FY26 Consolidated Revenue: ₹14.20 crore
• Q4 FY26 Consolidated Net Loss: ₹-5.16 crore
• FY26 Consolidated Revenue: ₹53.33 crore
• FY26 Consolidated Net Loss: ₹-1.71 crore
• Total Undisputed Statutory Dues Outstanding: ₹4.18 crore

What to track next

Investors should closely monitor the progress of the proposed Scheme of Arrangement and the shareholder approval process for related party transactions. Addressing the outstanding statutory dues will be critical for improving financial health and investor confidence.